Clearpoint Neuro (CLPT) Q2 2020 earnings summary

Executive summary

• Q2 revenue was $2.5M, down 5% YoY; COVID-19 disruptions to elective procedures and hospital capital purchases were partly offset by biologics and drug-delivery growth.

• Q2 net loss was $1.7M and operating loss was $1.5M; cash and equivalents totaled $16.0M at June 30, 2020.

Financial highlights

• Q2 total revenue was $2.478M vs. $2.606M YoY; service and other revenue rose to $885K from $412K, while product revenue fell to $1.593M from $2.194M.

• Q2 gross margin was 74% vs. 60% YoY, driven primarily by a greater contribution from services.

• Q2 operating expenses were $3.3M, up 15% YoY; operating loss was $1.475M vs. $1.293M, and net loss was $1.661M vs. $1.550M.

• H1 revenue was $5.593M vs. $5.079M; net loss was $3.716M vs. $2.771M, with basic and diluted EPS of $(0.24) in both periods.

Outlook and guidance

• No FY2020 forecast was offered because pandemic uncertainty clouds the timing of recovery in elective procedures, capital placements, and customer-sponsored trials.

• Elective procedures were not expected to fall again to April levels, but hospitals facing COVID-19 surges could suspend them; delayed March-April diagnostic workups were expected to defer resulting surgeries.

• The four-pillar growth strategy remained in execution despite management viewing the pandemic as a temporary setback.